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Immunomodulation of the gut associated lyn-
phoid tissue is a key issue in the clinical manage-
ment of inﬂammatory bowel disease (IBD). Often
toxic drugs are used to obtain clinical remission,
sometimes in already immunocompromized
patients. The presence of important co-morbidity
might also heavily affect the clinical strategy. Poly-
unsaturated fatty acids (PUFAs) might represent a
valid therapeutical option in IBD patients and
further controlled clinical studies are warranted.
Case report
This report presents the management of a
38-year-old Caucasian woman with ulcerative
colitis who had extra-intestinal manifestations
(polyarthritis) and mitral valve prolapse, and
whose treatment included essential fatty acids.
In 1998, at the age of 27, she presented to the
emergency department with 10 days of bloody
diarrhoea and lower abdominal cramping pain.
She described up to 15 bowel motions daily with
urgency, and approximately 3 kg weight loss.
She denied emesis or a family history for IBD
and/or colorectal cancer. She was a smoker with
no history of medical illness or surgery, and
denied recent antibiotic or non-steroidal anti-
inﬂammatory drug use. She had no known sick
contacts or exposure to at-risk foods. However,
she had experienced increased emotional stress
over the past several weeks.
Shewasclinicallydehydrated.Laboratoryinves-
tigations and inﬂammatory markers were remark-
able only for a moderately low haemoglobin
(100 g/L), a low blood ferritin (7 ng/mL) and a
high cholesterol (245mg/dL).
The patient was admitted to the hospital for
presumed infectious enterocolitis to start intrave-
nous hydration and symptomatic treatment.
Stool microbiology was negative for pathogens,
but faecal leukocytes were present. After 48 hours
with minimal response to therapy, she underwent
ﬂexible sigmoidoscopy and biopsies, which
showed friable and erythematous mucosa in a
diffuse circumferential distribution from the anal
verge to the splenic ﬂexure. There were no pseu-
domembranes. Histological evaluation revealed
acute inﬂammation without architectural distor-
tion consistent with either acute infectious colitis
or new inﬂammatory bowel disease favouring
ulcerative colitis.
The patient’s symptoms substantially resolved
over the next 3–4 days, and she was discharged
with a course of antibiotics.
However, a few days after discharge, she
returned with recurrent bloody diarrhoea and
abdominal pain. Aworking diagnosis of ulcerative
colitis was made and she was started on mesala-
zine 2.4 g daily with oral prednisone 40 mg daily.
After three days of this treatment, stool frequency
had decreased to twice a day, with rare blood-
tinged stools. The abdominal cramping had
improved, but still occurred episodically with
some tenesmus. Steroid side-effects included
depressed mood and insomnia, which resolved
as the dose was tapered.
Due to persistent rectal urgency, an ileocolono-
scopy was performed after six weeks; this showed
mild erythema and granularity from the rectum
to the sigmoid colon and in the ascending colon.
The transverse colonic mucosa and terminal
ileum were grossly normal. However, biopsies
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1throughout the colon revealed diffuse crypt archi-
tectural distortion. A daily mesalazine supposi-
tory (1 g) was added with improvement, and at
three months she remained in clinical remission
on mesalazine monotherapy.
Later onset of fatigue, palpitations, chest pain,
anxiety and headaches led to echocardiography
which disclosed mitral valve prolapse associated
with moderate mitral regurgitation. She was also
found to have arthrosis and chondropathy of the
right knee. She was prescribed bisoprolol hemifu-
marate (1.25 mg daily) for the heart, and rizatrip-
tan (10 mg) for the headaches. Her ulcerative
colitis then entered a new phase of exacerbation
and she was referred to the inﬂammatory bowel
disease clinic of Parma University Hospital. Clini-
cal assessment and proctosigmoidoscopy were
carried out and yielded a Mayo Clinic score of 8.
An eight-week course of tapering steroids was
started with clinical remission occurring after
three weeks. Continuing immunosuppressive and
biologic therapy were considered excessively high-
risk options given her predisposition to infective
endocarditis. She was, however, recruited to the
hospital’s colonoscopic surveillance programme.
Soon after stopping steroids there was another
exacerbation of the colitis, with a Mayo Clinic
score of 6. To minimize infective risk she was
started on budesonide 9 mg daily with some
beneﬁt (Mayo Clinic score 4), but after two
weeks the serum amylase became abnormal (426
U/L). Abdominal ultrasound was normal and it
was felt that this was a drug-related effect. The
budesonide was, therefore, stopped and amylase
returned to normal.
Withdrawal of the budesonide precipitated a
further relapse comprising diarrhoea and bleed-
ing, with a Mayo Clinic score of 8. Omega-3 unsa-
turated fatty acid therapy was commenced. The
PUFAs (EPA and DHA) were started at the dose
of 1 g twice daily, while mesalazine was main-
tained at 2.4 g daily. The PUFAs were very well-
tolerated and no side-effects were identiﬁed. Her
bowel frequency slowly decreased, and within a
week all rectal bleeding had resolved.
At 2 weeks, complete clinical and endoscopic
remission had been accomplished, with a Mayo
Clinic score of 0. PUFA therapy (1 g twice daily)
and mesalazine (2.4 g daily) were continued for
six weeks, reducing then to maintenance doses
of 1 g and 1.6 g daily, respectively, for the
succeeding 18 months. Surgical work-up for
mitral valve replacement was commenced.
Discussion
Although the aetiology of inﬂammatory bowel
disease remains unknown, it is believed that an
exaggerated intestinal immune response to other-
wise innocuous stimuli plays a key role in its
pathophysiology. Immune mediators actively
contribute to and amplify the pathogenic cascade
that initiates and perpetuates the inﬂammatory
response of the gut.
1,2
Increased dietary intake of certain types of n-3
PUFAs (e.g. EPA and DHA) can divert cell metab-
olism towards less active eicosanoids, thereby
modulating both the inﬂammatory response and
immune reactivity. Previous studies have accord-
ingly proposed a protective role from supplemen-
tary dietary intake of (n-3) PUFAs in IBD,
3,4
potentially comparable to the effects of mesala-
zine, which has clear efﬁcacy in the treatment of
acute ulcerative colitis and in the maintenance of
its remission.
5–8 Intraepithelial lymphocytes are
likely to be essential lymphoid cells that partici-
pate in the induction and regulation of the
mucosal immune response. The majority of
human and murine intraepithelial lymphocytes
are classiﬁed as T cells. And the presence of
large number of CD8+ T cells among these intra-
epithelial lymphocytes in subjects with ulcerative
colitis is quite signiﬁcant. Evidence exists to
prove that attenuation of liberated cytokines,
such as leukotriene A4 could affect recruitment
of CD8 and CD4 T cells and may beneﬁcially
modulate other pro- and anti-inﬂammatory
eicosanoids.
9
The essential fatty acids are a group of PUFAs
that are present in various nutrients but which
cannot be synthesized in the body.
10 Theyare com-
posed of two main types: the n-6 (oromega-6) and
n-3 (oromega-3) series. Essential fatty acids have a
number of important biological roles, including
cell membrane structure and function, and the
production of intermediate compounds called
eicosanoids. These eicosanoids act as intercellular
messengers and mediators of inﬂammation and
immune reactivity.
11 It has been shown that
increased dietary intake of certain types of n-3
PUFAs (e.g. EPA and DHA) can divert cell
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2metabolism towards less inﬂammatory eicosa-
noids, thereby modulating both the inﬂammatory
response and the immune reactivity.
11–14
Previous studies have proposed a protective
role from dietary n-3 PUFAs in human IBD,
15–17
given the knowledge that the biological effects of
EPA and DHA, encompass improving lipid pro-
ﬁles and reducing blood pressure,
18,19 inhibiting
the growth of tumour cells,
20 and modulating
symptoms in autoimmune and other inﬂamma-
tory diseases.
21–24
EPA and DHA are evidently important as well
as essential in the diet, but it is probably not their
amount that is directly responsible for the ben-
eﬁcial effects, but rather their inﬂuence on the
(n-6):(n-3) ratio, because both PUFA types
compete with the same enzymes for their conver-
sion to active metabolites.
7 It is, for example, rec-
ommended that the human diet should return to
a more balanced (n-6):(n-3) ratio of around 4:1
rather than the ratio of over 15:1 provided by
many current Western diets. Moreover, it has
been shown that dietary supplementation with
EPA and DHA produce signiﬁcant systemic
immune suppression. Epidemiological studies in
Eskimos reveal a low incidence of IBD compared
with other Western populations, thus supporting
the protective role of the dietary intake of (n-3)
PUFAs, since their diet is rich in ﬁsh oils.
Patients with chronic intestinal disorders, such
as inﬂammatory bowel disease, have generally
lower plasma n-3 PUFAs than normal subjects.
24
It is possible that the patients are, therefore, com-
promised, in that the competition for metabolism
between n-3 and n-6 moieties will favour the pro-
duction of the more inﬂammatory mediators.
Eicosanoids such as leukotriene B4 (LTB4), throm-
boxane A2, or prostaglandin E2, and cytokines are
implicated.
7 Most endogenously produced n-3
fatty acids appear to have therapeutic potential
in ulcerative colitis and perhaps also in Crohn’s
disease.
25 LTB4 synthesis in the colonic mucosa
of patients with ulcerative colitis and Crohn’s
disease is increased,
26 and it was proposed that
inhibition of its synthesis may contribute to the
therapeutic effects of the aminosalicylates used
in the treatment of irritable bowel disease.
4
Although the clinical studies dealing with the
use of n-3 PUFAs in IBD have yielded conﬂicting
results, this is probably the result of discrepancies
in patient selection and the vagaries of the
formulations and dosages used in the different
protocols. PUFA supplementation in patients
with proctocolitis has, however, been associated
with a reduction in disease activity.
26 The encoura-
ging ﬁndings in the present patient should encou-
rage further clinical evaluation.
Increasing evidence indicates that the fat com-
position of deﬁned formula diets is critically
important in their anti-inﬂammatory effects.
Given that many distinct PPARc ligands (PUFAs,
aminosalicylates and rosiglitazone) are effective
in ulcerative colitis, and that PPARc is expressed
in colonic mucosa,
27 the effect of dietary fat
manipulation using natural PPARc ligands is
worthy of further investigation in irritable bowel
disease.
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